Carpmaels & Ransford LLP
Client SatisfactionEPO opposition, strategic prosecution, and patent and SPC litigation are core pillars of the ‘very strong’ team at Carpmaels & Ransford LLP. David Wilson leads the firm’s dispute resolution team and has a proven track record in negotiating high-value licenses and settlement agreements. James Warner is noted for his adept handling of multi-opponent EPO opposition proceedings. IP transactions specialist Jake Marshall is singled out for his expertise in commercial agreements. Camilla Balleny frequently brings her contentious IP experience to bear on SPC and divisional filing strategies.
Testimonials
Collated independently by Legal 500 research team.
‘Carpmaels has strong industry knowledge and effectively integrates their litigators and patent attorneys.’
‘Aled Richards-Jones is a rising star who has excellent strategic judgment.’
‘Very strong team. Great depth and knowledge.'
‘Highly talented partners such as Edward Oates, Paul Kaufmann, Jennifer Antcliff and many others.’
‘The team are very experienced and can plan an effective overall strategy for a case.’
‘Harvey Adams has a great understanding and knowledge of long-running cases.’
‘The diverse team attorneys with whom I have had the pleasure of working are driven, smart, and willing to go the extra mile. They think about the strategy based on the goals of the company. They never just do something because it gets something allowed - they always consider the value.’
‘In both prosecution and oppositions, they come prepared to discuss the strategy in view of the company goals, not just the single patent on which we are working. They have already considered many different scenarios and are willing to walk through the pros and cons of each.'
Key clients
- Sanofi-Aventis
- Johnson & Johnson group, including various Janssen entities
- FibroGen, Inc.
- AMO Development, LLC (part of the Johnson & Johnson group)
- Novartis
- Takeda
- Regeneron Pharmaceuticals, Inc.
- Sidley Austin
Work highlights
- Instructed to help defend and enforce the patents that protect Johnson & Johnson’s biggest product, Stelara.
- Instructed by Janssen to revoke certain antibody patents (owned by Amgen) at the EPO and in the UK, to clear the way for the launch of its product, TECVAYLI.
Practice head
The lawyer(s) leading their teams.
Hugh Goodfellow, David Wilson, James Warner, Jake Marshall, Mark Chapman, Roger Lush